HAS Healthcare Advanced Synthesis SA (Biasca, Switzerland) achieves Carbon Neutrality

24 March 2023

TIBIO – Azienda ticinese selezionata tra gli attori chiave nel mercato mondiale dei prodotti chimici basati sulle biotecnologie

13 February 2023

Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs

6 February 2023

Helsinn and Immedica enter exclusive partnership for commercialisation of cancer supportive care products in core European markets

24 January 2023

Helsinn closes financing agreement with Oberland Capital

24 January 2023

Helsinn announces the appointment of Dr Melanie Rolli as Group Chief Executive Officer

17 January 2023

Helsinn closes financing agreement with Oberland Capital

17 January 2023